NCT02824185View on ClinicalTrials.gov

Combined Fluorocholine Positron Emission Tomography and Magnetic Resonance Imaging (FCH-PET/MRI) in Curative Treatment of a Hepatocellular Carcinoma

NACompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

June 14, 2017

Primary Completion Date

January 2, 2023

Study Completion Date

January 2, 2023

Conditions
Patients Eligible to a Curative Treatment for Primary HCC
Interventions
DEVICE

PET/MRI system (SIEMENS AG, Munich, Germany; distributed in France by SIEMENS S.A.S, Saint-Denis, France)

A PET/MRI examination will be performed once for all included patients, using injected fluorocholine, with a dose of 3MBq/kg, up to 2 months before HCC treatment.

Trial Locations (4)

38700

CHU de Grenoble, Servide d'Hépato-gastro-entérologie, La Tronche

69003

HCL, Hôpital Edouard Herriot, service d'hépato-gastro-entérologie, Lyon

Hospices Civils de Lyon, Hôpital Edouard Herriot, service d'hépato-gastro-entérologie, Lyon

69004

HCL, Hôpital de la Croix-Rousse, service d'Hépato-gastro-entérologie, Lyon

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT02824185 - Combined Fluorocholine Positron Emission Tomography and Magnetic Resonance Imaging (FCH-PET/MRI) in Curative Treatment of a Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter